Market Newsdesk

November 1, 2025 1:33 am

Zeekr Group Announces October 2025 Delivery Update

PR Newswire

HANGZHOU, China
, Nov. 1, 2025 /PRNewswire/ — ZEEKR Intelligent Technology Holding Limited (“Zeekr Group” or the “Company”) (NYSE: ZK), the world’s leading premium new energy vehicle group, today announced its delivery results for October 2025.

In October, Zeekr Group delivered a total of 61,636 vehicles across its Zeekr and Lynk & Co brands, representing increases of 9.8% year-over-year and 20.5% month-over-month. Specifically, the Zeekr brand delivered 21,423 vehicles, while Lynk & Co delivered 40,213 vehicles, thanks to the trust and support of over 2.15 million cumulative users.

About Zeekr Group

Zeekr Group, headquartered in Zhejiang, China, is the world’s leading premium new energy vehicle group from Geely Holding Group. With two brands, Lynk & Co and Zeekr, Zeekr Group aims to create a fully integrated user ecosystem with innovation as a standard. Utilizing its state-of-the-art facilities and world-class expertise, Zeekr Group is developing its own software systems, e-powertrain and electric vehicle supply chain. Zeekr Group’s values are equality, diversity, and sustainability. Its ambition is to become a true global new energy mobility solution provider.

For more information, please visit https://ir.zeekrgroup.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “future,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

Investor Relations Contact

In China:

ZEEKR Intelligent Technology Holding Limited
Investor Relations
Email: [email protected]

Piacente Financial Communications
Tel: +86-10-6508-0677
Email: [email protected]

In the United States:

Piacente Financial Communications
Brandi Piacente
Tel: +1-212-481-2050
Email: [email protected]

Media Contact

Email: [email protected]

View original content:https://www.prnewswire.com/news-releases/zeekr-group-announces-october-2025-delivery-update-302601559.html

SOURCE ZEEKR Intelligent Technology Holding Limited

October 31, 2025 11:37 pm

Tims China Announces Issuance of Senior Secured Convertible Notes and Amendment to Existing Convertible Notes

SHANGHAI and NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) — TH International Limited (Nasdaq: THCH), the exclusive master franchisee of Tim Hortons restaurants in China (“Tims China” or the “Company”), today announced that it has entered into a definitive agreement for the issuance of Senior Secured Convertible Notes. Additionally, THCH announced amendments to its existing 2024 unsecured convertible notes.

Transaction Overview

Tims China has entered into agreements providing for the issuance of senior secured convertible notes due September 2029 (“New Secured Notes”) in an aggregate principal amount of approximately US$89.9 million. The Company will use part of the proceeds from the issuance of the New Secured Notes for the repurchase of all outstanding amount due under its variable rate convertible senior notes due 2026.

The New Secured Notes will be convertible directly into newly issued ordinary shares of Tims China at a price equal to 110% of the five-day volume-weighted average share price (“VWAP”) prior to signing. The New Secured Notes are secured by a pledge of 100% of the shares of TH Hong Kong International Limited and an all-asset debenture of Tims China.

Concurrently, Tim Hortons Restaurants International GmbH (“THRI”) and Cartesian Capital Group have agreed to extend the maturity of their 2024 unsecured convertible notes from June 2027 to September 2029, with the conversion price reset to align with the New Secured Notes.

The transaction has been approved by the board of directors of the Company and is expected to close in the fourth quarter of 2025, subject to customary closing conditions, including required regulatory approvals in China.

Additional Information

Further details of these transactions will be provided in a Form 6-K to be filed with the U.S. Securities and Exchange Commission (SEC) and available on the SEC’s website by October 31, 2025.

FORWARD-LOOKING STATEMENTS

Certain statements in this earnings release may be considered forward-looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, such as the Company’s ability to further grow its business and store network, optimize its cost structure, improve its operational efficiency, and achieve profitable growth. Forward-looking statements are statements that are not historical facts and generally relate to future events or the Company’s future financial or other performance metrics. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “target,” “plan,” “expect,” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such forward looking statements. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by the Company and its management, as the case may be, are inherently uncertain and subject to material change. Factors that may cause actual results to differ materially from current expectations include various factors beyond management’s control, including, but not limited to, general economic conditions and other risks, uncertainties and factors set forth in the sections entitled “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in the Company’s Annual Report on Form 20-F, and other filings it makes with the Securities and Exchange Commission. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Except as required by law, the Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.

ABOUT TH INTERNATIONAL LIMITED

TH International Limited (Nasdaq: THCH) (“Tims China”) is the parent company of the exclusive master franchisees of Tim Hortons restaurants in mainland China, Hong Kong and Macau. Tims China was founded by Cartesian Capital Group and Tim Hortons Restaurants International GmbH, a subsidiary of Restaurant Brands International Inc. (TSX: QSR) (NYSE: QSR).

The Company’s philosophy is rooted in world-class execution and data-driven decision making and centered around true local relevance, continuous innovation, genuine community, and absolute convenience. For more information, please visit https://www.timschina.com.

INVESTOR AND MEDIA CONTACTS

Investor Relations

Gemma Bakx

[email protected]
, or [email protected]

Public and Media Relations

Patty Yu

[email protected]

October 31, 2025 10:19 pm

MaxsMaking Inc. Reports First Half of Fiscal Year 2025 Financial Results

PR Newswire

SHANGHAI
, Oct. 31, 2025 /PRNewswire/ — MaxsMaking Inc. (Nasdaq: MAMK) (“MaxsMaking” or the “Company”), a manufacturer of customized consumer goods with a focus on advanced technology and innovation, today announced its unaudited financial results for the first half of the fiscal year ended April 30, 2025.

First Half of Fiscal Year 2025 Financial Summary

Revenue was $12.40 million for the first half of fiscal year 2025, representing an increase of 27.43% from $9.73 million for the same period of last year.
Gross profit was $1.34 million for the first half of fiscal year 2025, compared to $1.98 million for the same period of last year.
Gross profit margin was 10.82% for the first half of fiscal year 2025, compared to 20.36% for the same period of last year.
Net income was $0.18 million for the first half of fiscal year 2025, compared to net income of $0.98 million for the same period of last year.
Basic and diluted earnings per A share were $0.02 for the first half of fiscal year 2025, compared to $0.13 for the same period of last year.

Mr. Xiaozhong Lin, Chairman and Chief Executive Officer of MaxsMaking, remarked: “In the first half of fiscal year 2025, we navigated a shifting business environment by scaling our domestic sales to secure stable revenue growth and strengthened market position, through various proactive initiatives such as trade-fair participation, targeted promotional events, expanded direct marketing and key-customer negotiations, and competitive pricing strategies. At the same time, we continued to diversify into Oceania, South America, and Africa to offset market headwinds in Asia, North America, and Europe. During this period, our total revenue increased by 27.43%, driven by a 51.89% surge in domestic sales and new customer acquisitions from the emerging markets. As global disruptions and uncertainties gradually subside, we believe our solid sales base will support a strong rebound, providing a renewed springboard for future growth.

“During this period, we increased research and development spending by 53.50% to advance production process technologies, customization capabilities. To address rising material, labor and bad-debt costs, we adopted a volume-first strategy to expand market share and better absorb fixed costs. While this temporarily compressed our margins, we view it as a strategic short-term trade-off that does not diminish our underlying profitability potential.”

“Furthermore, our successful Nasdaq IPO in July 2025 has strengthened our balance sheet and enhanced our capital resources to pursue additional strategic initiatives and market opportunities. As personalization and customization evolve from niche segments into mainstream consumer trends, we believe that our business is well positioned to leverage flexible pricing, expand value-added services, and enter a virtuous growth cycle, supported by our diversified market reach, growing product suite, accumulated technological expertise, and enhanced capital base.”

“Looking ahead, our current strategy, anchored in continuous product and technology innovation, will remain as the foundation for sustainable growth and global expansion, particularly in the North America market. We will continue to invest in R&D while maintaining strict cost-efficiency measures to execute this strategy efficiently, supporting long-term shareholder value, even amid a macroeconomic environment of both headwinds and tailwinds.”

First Half of Fiscal Year 2025 Financial Results

Revenue

Revenue was $12.40 million for the first half of fiscal year 2025, representing an increase of 27.43% from $9.73 million for the same period of last year. The increase was primarily attributable to an approximately $3.91 million increase in sales in mainland China, and partially offset by the decrease of approximately $1.18 million in sales in Asia (excluding mainland China). The increase in revenue in mainland China and the decrease in other Asian markets were mainly due to uncertainties in overseas markets, where customers’ demand and consumption prospects remained relatively weak, leading the Company to strengthen its domestic sales initiatives, such as increasing participation in trade fairs and promotional events, expanding direct marketing and business negotiations with key customers, and adopting more competitive pricing to strengthen its market position in mainland China.

	For the Six Months Ended				For the Six Months Ended				Change
	April 30, 2025				April 30, 2024				Change
Country/Region	Sales		As % of		Sales		As % of		Amount		%
Country/Region	Amount		Sales		Amount		Sales		Amount		%
Mainland China	$	11,459,301	92.38	%	$	7,544,314	77.50	%	$	3,914,987	51.89	%
Asia (excluding mainland China)		371,784	3.00	%		1,556,241	15.99	%		(1,184,457)	(76.11)	%
North America		59,069	0.48	%	`	123,884	1.27	%		(64,815)	(52.32)	%
Europe		427,115	3.44	%		499,126	5.13	%		(72,011)	(14.43)	%
Oceania		39,715	0.32	%		7,970	0.08	%		31,745	398.31	%
South America		11,634	0.09	%		2,468	0.03	%		9,166	371.39	%
Africa		35,616	0.29	%		–	–	%		35,616	100.00	%
Total	$	12,404,234	100	%	$	9,734,003	100	%	$	2,670,231	27.43	%

Cost of Revenue

Cost of revenue was $11.06 million for the first half of fiscal year 2025, representing an increase of 42.70% from $7.75 million for the same period of last year. The increase was primarily due to the increase in raw material cost and labor cost, as well as the effect of the Company’s strategic shift to a volume-driven model, which resulted in higher sales volume and corresponding higher production expenses.

Gross Profit

and Gross Profit Margin

Gross profit was $1.34 million for the first half of fiscal year 2025, compared to $1.98 million for the same period of last year.

Gross profit margin was 10.82% for the first half of fiscal year 2025, compared to 20.36% for the same period of last year. The decrease in gross profit margin was primarily due (i) an increase in raw material cost and labor cost, and (ii) the Company’s strategic shift toward a volume-driven model, which prioritizes market share growth over near-term margins.

Operating Expenses

Operating expenses were $1.17 million for the first half of fiscal year 2025, representing an increase of 27.01% from $0.92 million for the same period of last year.

Selling expenses were $0.29 million for the first half of fiscal year 2025, representing a decrease of 4.3% from $0.31 million for the same period of last year. The decrease is mainly due to the reduction in employee salaries.
General and administrative expenses were $0.42 million for the first half of fiscal year 2025, representing an increase of 32.37% from $0.31 million for the same period of last year. The increase was mainly due to an increase in the bad debt expense of approximately $95,000, as a result of the slow collection of accounts receivables.
Research and development expenses were $0.46 million for the first half of fiscal year 2025, representing an increase of 53.50% from $0.30 million for the same period of last year. The increase was primarily attributable to the research and development of five projects related to technologies for production processes.

Net Income

Net income was $0.18 million for the first half of fiscal year 2025, compared to $0.98 million for the same period of last year.

Basic and Diluted Earnings per Share

Basic and diluted earnings per A share were $0.02 for the first half of fiscal year 2025, compared to $0.13 for the same period of last year. Basic and diluted earnings per B share were $0.02 for the first half of fiscal year 2025, compared to $0.14 for the same period of last year.

Financial Condition

As of April 30, 2025, the Company had cash of $0.19 million, compared to $0.18 million as of October 31, 2024.

Net cash provided by operating activities was $0.85 million for the first half of fiscal year 2025, compared to net cash used in operating activities of $1.73 million for the same period of last year.

Net cash used in investing activities was $53,810 for the first half of fiscal year 2025, compared to $9,027 for the same period of last year.

Net cash used in financing activities was $0.78 million for the first half of fiscal year 2025, compared to net cash provided by financing activities of $1.83 million for the same period of last year.

Recent Development

On July 8, 2025, the Company completed its initial public offering (the “Offering”) of 1,625,000 A shares at a public price of US$4.00 per share. The gross proceeds were US$6.5 million from the Offering, before deducting underwriting discounts and commissions, and other expenses. The Company’s A shares began trading on the Nasdaq Capital Market on July 7, 2025, under the ticker symbol “MAMK.”

About MaxsMaking Inc.

Founded in 2007 and headquartered in Shanghai, MaxsMaking Inc. specializes in customized consumer goods with a focus on advanced technology and innovation. With production facilities in China’s Zhejiang and Henan provinces, the Company integrates digital production, software development, product design, brand management, online sales and international trade to deliver small-batch textile customization services. Its products include backpacks, shopping bags, aprons, and other promotional items. Using sustainable materials and proprietary order management technologies, MaxsMaking delivers high-quality, cost-effective products while emphasizing environmental protection and social responsibility. For more information, please visit the Company’s website: https://ir.maxsmaking.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions in this announcement. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For more information, please contact:

MaxsMaking Inc.
Investor Relations
Email: [email protected]

Ascent Investor Relations LLC

Tina Xiao

Phone: +1-646-932-7242
Email: [email protected]

MAXSMAKING INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF APRIL 30, 2025 (UNAUDITED) AND OCTOBER 31, 2024
IN U.S. DOLLARS, EXCEPT SHARE DATA

	April 30, 2025		October 31, 2024
	(Unaudited)
ASSETS
Current Assets
Cash	$	186,007	$	176,236
Accounts receivable, net		6,011,750		6,188,992
Due from related parties		5,554		–
Inventories		3,528,337		2,633,615
Prepayments and other current assets		6,825,994		7,452,317
Total current assets		16,557,642		16,451,160

Non-Current Assets
Property and equipment, net		120,785		119,125
Intangible assets, net		6,850		7,433
Right-of-use assets, net		117,526		86,441
Deferred tax assets		44,407		24,538
Deferred offering cost		1,058,003		986,206
Total non-current assets		1,347,571		1,223,743

Total Assets	$	17,905,213	$	17,674,903

LIABILITIES AND EQUITY
Current Liabilities
Short-term loans	$	2,173,189	$	2,785,965
Accounts payable		2,433,012		2,127,623
Contract liability		459,408		512,859
Income tax payable		892,739		859,194
Other payables and accrued liabilities		932,469		867,249
Due to related parties		737,188		149,757
Lease liabilities-current		97,190		47,895
Total current liabilities		7,725,195		7,350,542

Non-Current Liabilities
Lease liabilities-non current		6,776		–
Long-term loans		1,840,642		2,058,651
Total non-current liabilities		1,847,418		2,058,651

Total liabilities		9,572,613		9,409,193

COMMITMENTS AND CONTINGENCIES (NOTE 17)				–

Equity
A Shares (US$ 0.01 par value; 7,575,000 A Shares authorized, 7,575,000 A Shares issued and outstanding as of April 30, 2025 and October 31, 2024)		75,750		75,750
B Shares (US$0.01 par value; 7,425,000 B Shares authorized, 7,425,000 B Shares issued and outstanding as of April 30, 2025 and October 31, 2024)		74,250		74,250
Additional paid-in capital		1,712,492		1,712,492
Statutory surplus reserve		705,396		705,396
Retained earnings		5,972,806		5,806,881
Accumulated other comprehensive income		(529,822)		(421,542)
Total MaxsMaking Inc.’s Equity		8,010,872		7,953,227

Non-Controlling Interests		321,728		312,483

Total equity		8,332,600		8,265,710

Total Liabilities and Equity	$	17,905,213	$	17,674,903

MAXSMAKING INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
FOR THE SIX MONTHS ENDED APRIL 30, 2025 AND 2024
IN U.S. DOLLARS, EXCEPT SHARE DATA

	For The Six Months Ended
	April 30,
	2025		2024
Revenues	$	12,404,234		9,734,003
Cost of revenues		(11,061,783)		(7,751,700)
Gross profit	$	1,342,451		1,982,303

Operating expenses:
Sales and marketing expenses		(293,041)		(306,224)
General and administrative expenses		(416,039)		(314,290)
Research and development expenses		(458,025)		(298,381)
Total operating expenses	$	(1,167,105)		(918,895)

Income from operations	$	175,346		1,063,408

Other income (expense), net
Interest expenses		(84,275)		(69,615)
Interest income		135		326
Other income		42,771		14,848
Exchange gains		57,949		11,614
Other expenses		(17,126)		(11,713)
Income before income tax provision	$	174,800		1,008,868
Income tax benefit (expense)		370		(25,006)
Net income	$	175,170		983,862
Less: Net income attributable to non-controlling interest		9,245		41,455
Net income attributable to MaxsMaking Inc.		165,925		942,407

Other comprehensive income:
Foreign currency translation adjustment		108,280		13,554
Comprehensive income	$	283,450		997,416
Less: comprehensive income (loss) attributable to non-controlling interests		3,379		(9,286)
Comprehensive income attributable to MaxsMaking Inc.	$	280,071		1,006,702
Weighted Average Shares Outstanding- Diluted		15,000,000		15,000,000

Earnings per A share- basic and diluted	$	0.02		0.13
Earnings per B share- basic and diluted		0.02		0.14

MAXSMAKING INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED APRIL 30, 2025 AND 2024
IN U.S. DOLLARS, EXCEPT SHARE DATA

	For The Six Months Ended
	April 30,
	2025		2024
Cash Flows from Operating Activities:
Net income	$	175,170		983,862
Depreciation of property and equipment		50,879		14,133
Allowance for expected credit loss		119,131		8,529
Reversal of expected credit loss		(15,579)		(145)
Amortization of right-of-use assets		26,092		90,317
Amortization of intangible assets		506		511
Other current assets and other receivables		(402,681)		–
Changes in operating assets and liabilities:
Accounts receivable		8,324		(1,709,906)
Inventories		(5,247)		(91,692)
Prepayments and other current assets		951,385		(245,798)
Amount due from related party		(5,569)		422
Deferred tax assets		(960,210)		597
Operating lease-right of use assets		(58,178)		(45,183)
Deferred financing cost		(938,993)		(646,615)
Other current liabilities		75,276		–
Other non-current assets		–		50,162
Accounts payable		328,826		425,692
Income tax payable		42,114		22,280
Contract liability		(48,136)		(381,151)
Other payables and accrued liabilities		–		106,249
Lease liabilities		56,727		(161,742)
Amount due to related party		1,447,089		(147,967)
Net cash provided by/ (used in) operating activities		846,926		(1,727,445)

Cash Flows from Investing Activities:
Purchases of property and equipment		(53,810)		(9,027)
Net cash used in investing activities		(53,810)		(9,027)

Cash Flows from Financing Activities:
Capital contributions		–		70,305
Proceeds from third parties loans		–		239,015
Proceeds from bank borrowings		124,609		2,671,579
Repayments of borrowings to third parties		(255,316)		(729,763)
Repayment of bank borrowings		(650,735)		(421,828)
Net cash (used in)/ provided by financing activities		(781,442)		1,829,308

Effect of Exchange Rate Changes on Cash		(492)		1,404

Net Increase in cash		11,182		94,240
Cash, Beginning of Period		174,825		132,150
Cash, End of Period	$	186,007		226,390

Supplemental disclosure of cash flow information:	$
Cash paid for income tax	$	10,959		2,345
Cash paid for interest	$	29,403		64,902
Supplemental disclosure of non-cash flow information:
Right-of-use assets obtained in exchange for operating lease obligation	$	56,398		125,552

View original content:https://www.prnewswire.com/news-releases/maxsmaking-inc-reports-first-half-of-fiscal-year-2025-financial-results-302601549.html

SOURCE MaxsMaking Inc.

October 31, 2025 10:04 pm

Li Auto Inc. October 2025 Delivery Update

BEIJING, China, Nov. 01, 2025 (GLOBE NEWSWIRE) — Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today announced that it delivered 31,767 vehicles in October 2025. As of October 31, 2025, Li Auto’s cumulative deliveries reached 1,462,788.

As Li i6 has accumulated over 70,000 orders since its launch, the Company is taking all necessary steps to facilitate deliveries. Li Auto is also accelerating its global expansion efforts: it opened its first overseas authorized retail store in Uzbekistan in October, offering Li L9, Li L7, and Li L6 to the local market, with two more scheduled to open in Kazakhstan in November. The Company plans to prioritize market expansion in the Central Asia, Middle East, Europe, and Asia-Pacific as it steadily advances its global footprint.

As of October 31, 2025, the Company had 551 retail stores in 157 cities, 554 servicing centers and Li Auto-authorized body and paint shops operating in 225 cities. The Company also had 3,508 super charging stations in operation equipped with 19,417 charging stalls in China.

About Li Auto Inc.

Li Auto Inc. is a leader in China’s new energy vehicle market. The Company designs, develops, manufactures, and sells premium smart electric vehicles. Its mission is: Create a Mobile Home, Create Happiness (创造移动的家,创造幸福的家). Through innovations in product, technology, and business model, the Company provides families with safe, convenient, and comfortable products and services. Li Auto is a pioneer in successfully commercializing extended-range electric vehicles in China. While firmly advancing along this technological route, it builds platforms for battery electric vehicles in parallel. The Company leverages technology to create value for users. It concentrates its in-house development efforts on proprietary range extension systems, innovative electric vehicle technologies, and smart vehicle solutions. The Company started volume production in November 2019. Its current model lineup includes a high-tech flagship family MPV, four Li L series extended-range electric SUVs, and two Li i series battery electric SUVs. The Company will continue to expand its product lineup to target a broader user base.

For more information, please visit: https://ir.lixiang.com.

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “targets,” “likely to,” “challenges,” and similar statements. Li Auto may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”) and The Stock Exchange of Hong Kong Limited (the “HKEX”), in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. Statements that are not historical facts, including statements about Li Auto’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Li Auto’s strategies, future business development, and financial condition and results of operations; Li Auto’s limited operating history; risks associated with extended-range electric vehicles and high-power charging battery electric vehicles; Li Auto’s ability to develop, manufacture, and deliver vehicles of high quality and appeal to customers; Li Auto’s ability to generate positive cash flow and profits; product defects or any other failure of vehicles to perform as expected; Li Auto’s ability to compete successfully; Li Auto’s ability to build its brand and withstand negative publicity; cancellation of orders for Li Auto’s vehicles; Li Auto’s ability to develop new vehicles; and changes in consumer demand and government incentives, subsidies, or other favorable government policies. Further information regarding these and other risks is included in Li Auto’s filings with the SEC and the HKEX. All information provided in this press release is as of the date of this press release, and Li Auto does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:

Li Auto Inc.
Investor Relations
Email: [email protected]

Christensen Advisory
Roger Hu
Tel: +86-10-5900-1548
Email: [email protected]

October 31, 2025 9:15 pm

SNPS INVESTOR ALERT: Synopsys, Inc. Investors with Substantial Losses Have Opportunity to Lead the Synopsys Class Action Lawsuit

PR Newswire

SAN DIEGO
, Oct. 31, 2025 /PRNewswire/ — Robbins Geller Rudman & Dowd LLP announces that the Synopsys class action lawsuit – captioned Kim v. Synopsys, Inc., No. 25-cv-09410 (N.D. Cal.) – charges Synopsys, Inc. (NASDAQ: SNPS) and certain Synopsys top executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Sypnosis class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-synopsys-inc-class-action-lawsuit-snps.html

You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. Lead plaintiff motions for the Sypnosis class action lawsuit must be filed with the court no later than December 30, 2025, 2025.

CASE ALLEGATIONS: Synopsys provides electronic design automation software products used to design and test integrated circuits. Synopsys operates in two segments, Design Automation and Design IP.

The Synopsys class action lawsuit alleges that defendants throughout the class period failed to disclose that: (i) the extent to which Synopsys’ increased focus on artificial intelligence customers, which require additional customization, was deteriorating the economics of its Design IP business; (ii) as a result, “certain road map and resource decisions” were unlikely to “yield their intended results”; and (iii) the foregoing had a material negative impact on financial results.

The Synopsys investor class action further alleges that on September 9, 2025 Synopsys released its third quarter 2025 financial results, revealing that Synopsys’ “IP business underperformed expectations.” Specifically, the complaint alleges that Synopsys reported quarterly revenue of $1.740 billion, missing its prior guidance of between $1.755 billion and $1.785 billion, and reported net income of $242.5 million, a 43% year-over-year decline from $425.9 million reported for third quarter 2024. Synopsys also reported its Design IP segment accounted for approximately 25% of revenue and came in at $426.6 million, a 7.7% decline year-over-year, and provided guidance which implied that Design IP revenues will decline by at least 5% on a full-year basis in fiscal 2025, the Synopsys shareholder class action alleges. On this news, Synopsys’ stock price fell by nearly 36%, the complaint alleges.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Synopsys securities during the class period to seek appointment as lead plaintiff in the Synopsys class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Synopsys class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Synopsys class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Synopsys class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.

Contact:
      Robbins Geller Rudman & Dowd LLP
      J.C. Sanchez, Jennifer N. Caringal
      655 W. Broadway, Suite 1900, San Diego, CA 92101
      800-449-4900
      [email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/snps-investor-alert-synopsys-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-synopsys-class-action-lawsuit-302601507.html

SOURCE Robbins Geller Rudman & Dowd LLP

October 31, 2025 8:03 pm

NETGEAR® Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NETGEAR® Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN JOSE, Calif.–(BUSINESS WIRE)–
NETGEAR, Inc. (Nasdaq: NTGR), a global leader in intelligent networking solutions designed to power extraordinary experiences, today announced that it granted inducement equity awards to new employees who recently joined the company.

NETGEAR’s inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of NETGEAR, or following a bona-fide period of non-employment with NETGEAR, in each case as an inducement material to such individuals entering into employment with NETGEAR pursuant to Nasdaq Listing Rule 5635(c)(4).

The inducement awards granted to new employees joining NETGEAR consist of awards of time-based restricted stock units (“RSU’s”) covering 50,142 shares of NETGEAR common stock. One-third (1/3rd) of the total number of shares subject to each RSU Award will vest on the one-year anniversary of the RSU Award’s vesting commencement date and one-twelfth (1/12th) of the total number of shares subject to each RSU Award will vest in equal quarterly installments thereafter, in each case subject to each award recipient providing continued service with NETGEAR through the applicable vesting dates.

The inducement award granted to one of the new employees also includes an award of performance-based RSU’s with a target amount of 10,417 shares of NETGEAR’s common stock. The number of shares subject to the PSU Award that become eligible to vest (the “Vesting Eligible PSUs”) will be determined based on how NETGEAR’s total shareholder return (“TSR”) compares to the TSRs of the companies in the Nasdaq Telecommunications Index (IXTC) over the multi-year performance period beginning on April 23, 2025 and ending on December 31, 2027. The Vesting Eligible PSUs, if any, will vest on the third anniversary of the PSU Award’s grant date, subject to the employee’s continued service with NETGEAR through that date.

About NETGEAR, Inc.

Founded in 1996 and headquartered in the USA, NETGEAR® (NASDAQ: NTGR) is a global leader in innovative networking technologies for businesses, homes, and service providers. NETGEAR delivers a wide range of award-winning, intelligent solutions designed to unleash the full potential of connectivity and power extraordinary experiences. For businesses, NETGEAR offers reliable, easy-to-use, high-performance networking solutions, including switches, routers, access points, software, and AV over IP technologies, tailored to meet the diverse needs of small and medium enterprises. NETGEAR’s consumer products deliver advanced connectivity, powerful performance, and enhanced security features right out of the box, designed to help keep families safe online, whether at home or on the go. More information is available from the NETGEAR Press Room or by calling (408) 907-8000. Connect with NETGEAR: Facebook, Instagram and the NETGEAR blog at NETGEAR.com.

©2025 NETGEAR, Inc. NETGEAR and the NETGEAR logo are trademarks and/or registered trademarks of NETGEAR, Inc. and/or its affiliates in the United States and/or other countries. Other brand and product names are for identification purposes only and may be trademarks or registered trademarks of their respective holder(s). The information contained herein is subject to change without notice. NETGEAR shall not be liable for technical or editorial errors or omissions contained herein. All rights reserved.

Source: NETGEAR-F

View source version on businesswire.com: https://www.businesswire.com/news/home/20251031347697/en/

NETGEAR Investor Relations

Erik Bylin

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Consumer Electronics Security Technology Software Networks Internet Hardware

MEDIA:

Logo

October 31, 2025 7:54 pm

Quantum BioPharma Ltd. Provides Corporate Update

TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K9A) (“Quantum” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that pursuant to the entry into its previously announced at the market offering agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”) on February 16, 2024, announces today, the Company at its discretion may offer and sell, from time to time, through Wainwright as sales agent, Class B Subordinate Voting Shares in the capital of the Company (“ClassBShares”) having an aggregate offering price of up to US$21,225,000 (the “ATM Offering”). A cash commission of 3.0% on the aggregate gross proceeds raised under the ATM Offering will be paid to Wainwright in connection with its services.

Sales of the Class B Shares under the Prospectus will be made in transactions that are deemed to be “at-the-market” offering as defined in Rule 415(a)(4) promulgated under the Securities Act, including sales made directly on or through the Nasdaq Stock Market LLC (“Nasdaq”). The Class B Shares will be distributed at the prevailing market prices at the time of each sale. As a result, prices may vary as between purchasers and during the period of distribution. No Class B Shares in the ATM Offering will be sold on the Canadian Securities Exchange (the “CSE”) or any other trading market in Canada.

The volume and timing of sales, if any, will be determined at the sole discretion of the Company’s management and in accordance with the terms of the ATM Agreement. If the Company chooses to sell Class B Shares under the ATM Offering, the Company intends to use the net proceeds of the ATM Offering (i) to fund our various clinical studies, trials and development programs, (ii) to fund research and development, and (iii) for general corporate purposes and working capital.

The ATM Offering is being made in the United States pursuant to a registration statement on Form F-3 (File No. 333-276264) filed under the Securities Act of 1933, as amended (the “SecuritiesAct”), with the Securities and Exchange Commission (the “SEC”) and declared effective on January 4, 2024 (the “RegistrationStatement”), the base prospectus contained in the Registration Statement (the “Base Prospectus”) and the prospectus supplement dated October 31, 2025 (“Prospectus Supplement”, together with Base Prospectus, the “Prospectus”) filed with the SEC.

You can review our SEC filings, the Registration Statement and Prospectus by accessing the SEC’s internet site at www.sec.gov or on the Company’s website at www.quantumbiopharma.com, through which you can access our SEC filings.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About
Quantum BioPharma Inc.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly-owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) (“Lucid-MS”). Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum has also licensed UNBUZZD™, a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption for use in the consumer recreational sector, to Celly Nutrition Corp. (“Celly Nu”) and is entitled to a royalty on the revenue generated by Celly Nu from sales of products created using the technology rights granted under the licensing agreement. Quantum continues its R&D activities to develop novel formulations for alcohol misuse disorders and continues the development of such treatments for use in the healthcare sector. Quantum maintains a portfolio of strategic investments through its wholly-owned subsidiary, FSD Strategic Investments Inc., which represent loans secured by residential or commercial property.

Cautionary
Note
Regarding
Forward-Looking
Information

This press release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable securities laws. Any statements that are contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “plans”, “expects”, “expected”, “scheduled”, “estimates”, “intends”, “anticipates”, “hopes”, “planned” or “believes”, or
variations of such words and phrases, or states that certain actions, events or results “may”, “could”, “would”, “might”, “potentially” or “will” be taken, occur or be achieved. More particularly, and without limitation, this press release contains forward-looking statements contained in this press release include statements concerning the future of Quantum and are based on certain assumptions
that
Quantum
has
made
in
respect
thereof
as
of
the
date
of
this
press
release,
including
those
relating
to
future
sales
of Class B Shares under the ATM Offering, the offering price therefor and the use of proceeds thereof. Quantum cannot give any assurance that such forward-looking statements will prove to have been correct.

Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. The Company cautions that although it believes the expectations and material factors and assumptions reflected in these forward-looking statements are reasonable as of the date hereof, there can be no assurance that these expectations, factors and assumptions will prove to be correct and these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to a number of known and unknown risks and uncertainties including, but not limited to: the timing and ability to satisfy all applicable listing and regulatory requirements of the CSE and Nasdaq; the fact that the drug development efforts of the Company and Lucid are at a very early stage; the fact that preclinical drug development is uncertain, and
the drug product candidates of the Company and Lucid may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company and Lucid; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the potential inability to obtain
or
maintain
regulatory
approval
of
the
drug
product
candidates
of
the
Company
and
Lucid;
the
introduction
of
competing
drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company and Lucid; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen
issues;
the
potential
inability
to
obtain
adequate
financing;
the
potential
inability
to
obtain
or
maintain
intellectual
property protection for the drug product candidates of the Company and Lucid; the inability of the Company to sell under the ATM Offering or upon the terms outlined herein; the prices at which the Company may sell the Class B Shares in the ATM Offering; and other risks. Accordingly, readers should not place undue reliance on the forward-looking statements contained in this press release, which speak only as of the date of this press release.

Further information regarding factors that may cause actual results to differ materially are included in the Company’s annual and other
reports
filed
from
time
to
time
with
the
Canadian
Securities
Administrators
on
SEDAR+
(

www.sedarplus.ca

)

and
with
the
SEC
on EDGAR (
www.sec.gov),
including the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2024, the Prospectus and Registration Statement, each under the heading “Risk Factors”. This list of risk factors should not be construed as exhaustive.
Readers
are
cautioned
that
events
or
circumstances
could
cause
results
to
differ
materially
from
those
predicted,
forecasted or projected. The forward-looking statements contained in this document speak only as of the date of this document. Quantum does not undertake any obligation to publicly update or revise any forward-looking statements or information contained herein, except as required by applicable laws. The forward-looking statements contained in this document are expressly qualified by this cautionary
statement.

Neither
the
CSE
nor
its
regulation
services
provider
accept
responsibility
for
the
adequacy
or
accuracy
of
this
release.

Contacts:

Quantum BioPharma Inc.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board, Quantum BioPharma Inc.
Email: [email protected]
Telephone: (833) 571-1811

Investor Relations

Investor Relations: [email protected]
General Inquiries: [email protected]

October 31, 2025 6:29 pm

Metsera Issues Statement in Response to Litigation

PR Newswire

NEW YORK
, Oct. 31, 2025 /PRNewswire/ — Metsera, Inc. (NASDAQ: MTSR) (“Metsera” or the “Company”) today issued the following statement in response to litigation filed against the Company by Pfizer:

“Metsera disagrees with the allegations in Pfizer’s complaint and will address them in the Delaware Court of Chancery.”

Disclosure Notice

This release contains forward-looking information about, among other topics, Pfizer’s proposed acquisition of Metsera, Pfizer’s and Metsera’s pipeline products, including their potential benefits, potential best-in-class status, differentiation, profile and dosing, potential clinical trials, and the anticipated timing of completion of the proposed acquisition, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties relating to Pfizer’s proposed acquisition of Metsera include, among other things, risks relating to Pfizer’s litigation against the Company, including expenses from defending the litigation, potential damages or other losses resulting from the litigation, the impact of the litigation on the Company, its business and the market price of the Company’s common stock and the impact of the litigation on Novo Nordisk’s unsolicited proposal, risks related to the satisfaction or waiver of the conditions to closing the proposed acquisition (including the failure to obtain necessary regulatory approvals and failure to obtain the requisite vote by Metsera stockholders) in the anticipated timeframe or at all, including the possibility that the proposed acquisition does not close; the possibility that more competing offers may be made; risks related to the ability to realize the anticipated benefits of the proposed acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the transaction making it more difficult to maintain business and operational relationships, including Metsera’s ability to attract and retain highly qualified management and other clinical and scientific personals; negative effects of this announcement or the consummation of the proposed acquisition on the market price of Pfizer’s or Metsera’s common stock and/or operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the proposed acquisition or Metsera’s business; other business effects and uncertainties, including the effects of industry, market, business, economic, political or regulatory conditions; future exchange and interest rates; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws, regulations or policy; changes in tax and other laws, regulations, rates and policies; the uncertainties inherent in business and financial planning, including, without limitation, risks related to Pfizer’s business and prospects, adverse developments in Pfizer’s markets, or adverse developments in the U.S. or global capital markets, credit markets, regulatory environment, tariffs and other trade policies or economies generally; future business combinations or disposals; uncertainties regarding the commercial success of Metsera’s pipeline products or Pfizer’s commercialized and/or pipeline products; risks associated with Metsera conducting clinical trials and preclinical studies outside of the United States; Metsera’s reliance on third parties to conduct clinical trials and preclinical studies and for the manufacture and shipping of its product candidates; the risk that Metsera’s product candidates are associated with side effects, adverse events or other properties or safety risks; risks associated with Metsera’s license and collaboration agreements and future strategic alliances; Metsera’s ability to obtain, maintain, defend and enforce patent or other intellectual property protection for current or future product candidates or technology; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with initial, preliminary or interim data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; whether and when drug applications may be filed in any jurisdictions for Pfizer’s or Metsera’s pipeline products for any potential indications; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether any such products will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of such products; uncertainties regarding the impact of COVID-19; and competitive developments.

You should carefully consider the foregoing factors and the other risks and uncertainties that affect the businesses of Pfizer and Metsera described in the “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results” (in the case of Pfizer) and “Special Note regarding Forward Looking Statements” (in the case of Metsera) sections of their respective Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents filed by either of them from time to time with the U.S. Securities and Exchange Commission (the “SEC”), all of which are available at

www.sec.gov

. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Pfizer and Metsera assume no obligation to, and do not intend to, update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. Neither Pfizer nor Metsera gives any assurance that it will achieve its expectations.

Additional Information and Where to Find It

In connection with Pfizer’s proposed acquisition of Metsera, Metsera has filed documents with the SEC, including preliminary and definitive proxy statements relating to the proposed transaction. The definitive proxy statement has been mailed to Metsera’s stockholders in connection with the proposed transaction. This communication is not a substitute for the proxy statement or any other document that may be filed by Metsera with the SEC. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PRELIMINARY AND DEFINITIVE PROXY STATEMENTS AND ANY OTHER DOCUMENTS THAT HAVE BEEN OR WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Any vote in respect of resolutions to be proposed at Metsera’s stockholder meeting to approve the proposed transaction or other responses in relation to the proposed transaction should be made only on the basis of the information contained in Metsera’s proxy statement. Investors and security holders may obtain free copies of these documents and other related documents filed with the SEC at the SEC’s web site at

www.sec.gov

, or at

www.metsera.com

.

No Offer or Solicitation

This communication is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.

Participants in the Solicitation

Metsera and its directors, executive officers and other members of management and employees, under SEC rules, may be deemed to be “participants” in the solicitation of proxies from stockholders of Metsera in favor of the proposed transaction. Information about Metsera’s directors and executive officers is set forth in Part III of Metsera’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the SEC on March 26, 2025. Additional information concerning the interests of Metsera’s participants in the solicitation, which may, in some cases, be different than those of Metsera’s stockholders generally, is set forth in Metsera’s proxy statement relating to the proposed transaction. These documents are available free of charge at the SEC’s web site at

www.sec.gov

and at

www.metsera.com

.

View original content:https://www.prnewswire.com/news-releases/metsera-issues-statement-in-response-to-litigation-302601500.html

SOURCE Metsera, Inc.

October 31, 2025 6:25 pm

The Home Depot and The Home Depot Foundation commit $1 million to Hurricane Melissa relief efforts

PR Newswire

ATLANTA
, Oct. 31, 2025 /PRNewswire/ — The Home Depot and The Home Depot Foundation are committing $1 million in product donations, nonprofit grants and other support to provide immediate relief and long-term recovery support to Jamaica and other Caribbean communities devastated by Hurricane Melissa, one of the strongest storms in the region’s history.

Hurricane Melissa made landfall in Jamaica on October 28 as a Category 5 hurricane, resulting in loss of life as well as widespread destruction, including severe flooding, structural collapse and extensive power outages. Over 25,000 residents remain in emergency shelters. Full recovery may take several years.

The Home Depot Foundation is supporting critical resources for immediate relief efforts, including grants to World Central Kitchen to partner with local chefs for emergency meal distribution in Jamaica, Haiti, and the Bahamas, and to Convoy of Hope and Operation Blessing to purchase essential supplies. The Foundation will continue working with its nonprofit partners to facilitate both short-term response and long-term recovery in the coming weeks and months.

“Our hearts go out to the people of Jamaica and the broader Caribbean region as they recover from Hurricane Melissa,” said Erin Izen, executive director of The Home Depot Foundation. “Our teams are working around the clock with nonprofit partners to deliver emergency aid and lay the groundwork for long-term recovery.”

The Home Depot will donate urgently needed disaster relief and building products and supplies, such as generators, water, toolkits, flashlights, solar lights and other cleanup supplies, to support immediate relief efforts. Further, responding to requests from associates and customers, the company has set up its Miami stores, as well as 30 stores in the New York Metro region, to serve as hubs to expedite orders to impacted communities on the island.

Prior to hurricane season each year, The Home Depot stocks its warehouses and other supply chain locations with essential supplies for hurricane response and recovery, allowing these critical products to get to disaster zones quickly.

“The Home Depot is uniquely positioned to provide disaster-impacted communities with the support they need today, as they look to recover and clean up, and in the future, as they turn to rebuilding,” said Jason Arigoni, vice president of field merchandising for The Home Depot. “We’re here to help.”

About The Home Depot

The Home Depot is the world’s largest home improvement specialty retailer. At the end of the second quarter, the company operated more than 2,353 retail stores, over 800 branches and more than 325 distribution centers that directly fulfill customer orders across all 50 states, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, Guam, 10 Canadian provinces and Mexico. The company employs over 470,000 associates. The Home Depot’s stock is traded on the New York Stock Exchange (NYSE: HD) and is included in the Dow Jones industrial average and Standard & Poor’s 500 index.

About The Home Depot Foundation 
The Home Depot Foundation, a nonprofit supported by The Home Depot (NYSE: HD), works to improve the homes and lives of U.S. veterans, support communities impacted by natural disasters and train skilled tradespeople to fill the labor gap. Since 2011, the Foundation has invested more than $600 million in veteran causes and improved more than 65,000 veteran homes and facilities. The Foundation has pledged to invest $750 million in veteran causes by 2030 and $50 million in training the next generation of skilled tradespeople through the Path to Pro program by 2028. To learn more about The Home Depot Foundation visit HomeDepotFoundation.org and follow us on X @HomeDepotFound and on Facebook and Instagram @HomeDepotFoundation.

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-home-depot-and-the-home-depot-foundation-commit-1-million-to-hurricane-melissa-relief-efforts-302601496.html

SOURCE The Home Depot Foundation

October 31, 2025 6:22 pm

Datavault AI Issues Formal Response to Wolfpack Research’s Malicious Short Report; Company Affirms the Strength of Its Intellectual Property, Leadership, and Strategic Direction

PHILADELPHIA, Oct. 31, 2025 (GLOBE NEWSWIRE) — via IBN — Datavault AI (NASDAQ: DVLT) (“Datavault,” “DVLT,” or the “Company”), a leader in data tokenization and management, has noted that Wolfpack Research recently issued a self-serving and malicious short report targeting the Company and its Chief Executive Officer, Nathaniel T. Bradley. The Company strongly condemns this action and issues the following formal statement:

1. The Wolfpack Research Report Contains False and Defamatory Claims Aimed at Manipulating DVLT Stock for Financial Gain

The Wolfpack Research report includes numerous false, misleading, and defamatory statements intended to manipulate Datavault AI’s stock for the financial benefit of short sellers.

These claims lack factual foundation and have caused reputational harm to the Company and its stockholders. Wolfpack Research has openly acknowledged its short position in DVLT shares—demonstrating that its so-called “research” is driven by self-interest rather than truth.

“It’s obvious that these actors are financially benefitting from spreading false information,” said Nathaniel Bradley, Chief Executive Officer of Datavault AI. “We intend to file suit to hold Wolfpack Research accountable for its malicious conduct and to protect the rights of our shareholders.”

Short selling is a recognized market practice; however, intentional market manipulation through false and defamatory statements is not. The Company is evaluating Wolfpack Research’s actions and will pursue all legal remedies available under applicable law.

2. Datavault AI Has Engaged Legal Counsel and Formally Demanded Wolfpack Research Cease and Desist its Tortious Conduct

Datavault AI has retained Paul Hastings LLP and Dickinson Wright PLLC to advise on litigation strategy and regulatory action. The Company is evaluating its legal rights and intends to pursue all available remedies to protect its reputation and the legitimate interests of its stockholders.

Jacob Frenkel, Securities Enforcement Practice Chair at Dickinson Wright PLLC and lead litigation counsel for Datavault AI, stated: “the proper place for such purveyors and backers of ‘short and distort’ content is in a defendant’s chair in a courtroom, and that is exactly where the Company intends to put Wolfpack Research. Such abusive, fraudulent and manipulative practices mislead the market, sow distrust and harm shareholders. Mr. Bradley is committed to acting with the best interest of his Company’s shareholders, which is the precise reason for pursuing legal recourse against such defamatory report-writers. The lawsuit will spell out the false and misleading statements with specificity to the point of being a roadmap for federal enforcement authorities also to put the authors and instigators of the Wolfpack Research report in a defendant’s chair.”

3. Datavault AI Reaffirms the Strength of Its Intellectual Property and Strategic Value

Datavault AI’s value is anchored in its robust intellectual property portfolio, which comprises over 70 U.S. and international patents covering AI-driven data valuation, inaudible audio signal technology, blockchain tokenization frameworks, and enterprise data monetization systems.

“Our strategy is rooted in IP and execution, not speculation,” said Bradley. “The technology we’ve developed is already creating value across industries —from digital identity and healthcare to acoustic data and real-world asset tokenization. That foundation is unshakable.”

Datavault’s IP portfolio provides licensing revenue opportunities and a formidable barrier to entry for competitors. Recent patent grants include those covering carbon-credit tokenization on blockchain, virtual-reality data integration, and AI-driven audio tracking systems.

4. Professional History of Nathaniel T. Bradley

Nathaniel T. Bradley is a prolific American inventor and entrepreneur with more than two decades of experience in mobile marketing, audio processing, AI, and data monetization. He founded AudioEye, Inc. (NASDAQ: AEYE), pioneering digital accessibility technology used worldwide, and later Augme Technologies / Hipcricket, a mobile advertising platform that served Fortune 500 clients. Bradley was recognized as an EY Entrepreneur of the Year Finalist and received the Edison Gold Award for Social Impact.

At Datavault AI, Bradley has led the development of innovations in AI data valuation, blockchain for real-world asset (RWA) tokenization, and AI-powered audio communication through the Company’s ADIO® technology. His reputation for building mission-driven, patent-protected platforms is widely recognized across both technology and capital markets.

5. Recent Successes and Milestones

Formed a strategic alliance with NYIAX to enable smart-contract data exchanges.
Completed the acquisition of CompuSystems Inc. (CSI) assets, expanding enterprise event data capabilities.
Launched the WiSA E Endeavour™ Receiver Module through the Company’s Acoustic Science division.
Partnered with Nature’s Miracle Holding Inc. and Harrison Global Holdings Inc. to launch “The X Club” for the global XRP community.
Signed a 12-month national media series with New to The Street to enhance investor visibility.
Clarified executive vesting disclosures to reinforce corporate governance transparency.
Announced the incorporation and preparation of launching four independent data-exchanges – International Elements Exchange Inc., International NIL Exchange Inc., Information Data Exchange Inc., and American Political Exchange Inc., leveraging Datavault AI’s patent portfolio (now exceeding 70 assets) and targeting real-world asset tokenization, NIL rights monetization, corporate data marketplaces and political donation transparency.

About Datavault AI Inc.

Datavault AI™ (Nasdaq: DVLT) is at the forefront of AI-driven data experiences, valuation, and monetization. The company’s cloud-based platform delivers comprehensive solutions with a collaborative emphasis across its Acoustic Science and Data Science Divisions. Datavault AI’s Acoustic Science Division features Wisam®, ADIO®, and Sumerian® patented technologies, along with industry-leading foundational spatial and multichannel wireless HD sound transmission technologies, including IP for audio timing, synchronization, and multi-channel interference cancellation. The Data Science Division harnesses high-performance computing to offer solutions for experiential data perception, valuation, and secure monetization. Datavault AI’s cloud-based platform serves diverse industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy, and more. The Information Data Exchange® (IDE) enables Digital Twins and licensing of name, image, and likeness (NIL) by securely linking physical real-world objects to immutable metadata, promoting responsible AI with integrity. Datavault AI’s technology suite is fully customizable, featuring AI and Machine Learning (ML) automation, third-party integrations, detailed analytics, marketing automation, and advertising monitoring. The company is headquartered in Beaverton, OR. Learn more at www.dvlt.ai.

Forward-Looking Statements

Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will,” “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Forward-looking statements in this press release include, without limitation, those related to the Company’s planned actions against Wolfpack Research, the Company’s prospects and licensing revenue opportunities. Such uncertainties and risks include, but are not limited to, the results of our planned actions against Wolfpack Research, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, competitive factors, and other factors discussed in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that the Company has filed or may subsequently file with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of the Company’s management team and speak only as of the date hereof, and the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Corporate Communications:

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

Media Contact:

[email protected]